Virta Health

A doctor, a coach, and your blood sugar - all in one app

Somewhere this morning, a person who was told they would inject insulin for the rest of their life opened an app instead of a syringe. They logged a fasting glucose reading. A health coach replied within minutes. A physician adjusted a plan. By lunch, the dose was lower. This is an ordinary Tuesday at Virta Health, and it is also a quiet argument with most of modern medicine.

Virta is a digital health company headquartered in Denver, Colorado, built around one stubborn claim: type 2 diabetes can be reversed, not merely managed. Roughly 900 people work toward that across five continents. More than 100,000 members have gone through the program. The company crossed $160 million in annualized revenue in 2025, growing north of 80% year over year. None of that is the interesting part. The interesting part is the claim itself, which the rest of the industry spent decades calling impossible.

The standard of care had a quiet assumption built in

For most of the last century, the script for type 2 diabetes ran one direction. Diagnose. Medicate. Add a second medication. Add insulin. Manage the decline. The disease was treated as a one-way street, and the pharmacy was the toll booth you paid at forever. It worked, in the sense that it kept people alive. It also quietly assumed that the underlying metabolism could never improve.

That assumption is expensive. Diabetes and obesity drive an enormous share of healthcare spending, and the newest weight-loss drugs - the GLP-1 class, Ozempic and Wegovy and their cousins - arrived with results so good and price tags so steep that employers and insurers began to sweat. The drugs work while you take them. Stop, and the weight often returns. For a payer covering thousands of employees, "effective but indefinite and costly" is not a solution. It is a subscription with no exit.

An Ironman found out he was prediabetic. That was the spark.

Sami Inkinen was, by any reasonable measure, the last person who should have been worried about his metabolism. He was an elite Ironman triathlete. He had already co-founded Trulia, the real estate marketplace that went public and was later acquired by Zillow Group. He was fit, successful, and - it turned out - prediabetic. The lab results did not care about his finish times.

Inkinen did the thing entrepreneurs do with inconvenient facts: he got obsessive. He and his wife rowed a boat across the Pacific Ocean, unsupported, on a high-fat low-carbohydrate diet, partly to prove a point about fuel and metabolism. Then in 2014 he co-founded Virta with two scientists who had spent careers on exactly this question - Dr. Stephen Phinney and Dr. Jeff Volek, researchers who had effectively written the textbooks on nutritional ketosis and low-carbohydrate physiology.

The bet was simple to state and hard to pull off. If you change what someone eats - precisely, individually, and with real medical supervision - you can lower blood sugar enough to reduce or eliminate medications. The trick was never the diet alone. Plenty of diets work for two weeks. The trick was delivering clinical-grade care continuously, at scale, to people who live nowhere near a clinic.

Continuous Remote Care, which is a fancy way of saying always on

Virta's platform goes by the deliberately unglamorous name Continuous Remote Care. A member gets a mobile app that pulls in biometric data - blood glucose, blood ketones, weight - and routes it to a dedicated care team. Behind the app sits a physician who can adjust medications and a health coach who handles the daily, human, slightly-tedious work of behavior change. AI-driven algorithms personalize the nutrition plan and flag when something needs a clinician's eye.

It is, functionally, a full-stack medical clinic that fits in a pocket. The model has since expanded well beyond diabetes into sustainable weight loss and GLP-1 management - because once you can lower someone's blood sugar through food and coaching, the same machinery works on obesity.

The numbers that made insurers pick up the phone

Plenty of wellness companies promise transformation. Virta's distinguishing move was to publish peer-reviewed clinical evidence and then sell against it. The headline results are the kind that make a skeptical medical director read twice: at one year, 94% of patients using insulin reduced or eliminated their dose, and 63% of all diabetes prescriptions were eliminated - with an average HbA1c drop alongside.

That evidence is what turned a science project into a business. Virta sells to employers, health plans, and government payers - more than 500 of them - including large employers like United Airlines and UPS and 20-plus national and regional health plans. The pricing is the unusual part: it is tied to outcomes. Virta largely gets paid when patients improve and drug spend falls. If the program does not work, the invoice does not fully come due.

One hundred million people. They wrote the number down.

Virta's stated mission is to reverse type 2 diabetes and metabolic disease in 100 million people. It is the sort of round, audacious figure that usually lives on a recruiting slide and dies in a quarterly report. What makes it less of a poster and more of a plan is that the unit economics point the same direction as the mission. Every member who reverses their disease is both a clinical win and a payer who saves money - which means doing more good and selling more contracts are, unusually, the same motion.

The culture follows the science. Virta is remote-friendly and evidence-obsessed, staffed by clinicians, behavioral scientists, engineers, and data scientists who are pointed at a single metric: did the patient actually get better. The behavioral-science side matters more than the diet headlines suggest. Changing what a person eats, every day, for years, is a harder engineering problem than any algorithm.

The GLP-1 era made Virta's question urgent

Here is the irony Virta did not plan for. The GLP-1 boom should have been a threat - a wildly effective drug class arriving to solve the exact problem Virta solves with food. Instead it sharpened the company's pitch. The drugs are powerful and they are permanent expenses, and the moment a member stops taking them the weight tends to come back. Virta's 2025 data put a number on the difference: people who tapered off GLP-1s under medical guidance were eight times more likely to keep losing weight than those who quit cold.

So Virta did not fight the drugs. It absorbed them. The Responsible Prescribing program uses GLP-1s when they help, then builds the off-ramp - the nutrition, coaching, and supervision that lets people keep the results without the indefinite bill. For a payer staring down runaway drug spend, "use the drug, then graduate from it" is a more attractive sentence than "pay forever."

Return to that ordinary Tuesday. The person who opened an app instead of reaching for a syringe is not an outlier or a testimonial. They are the entire thesis, repeated 100,000 times and counting. A decade ago, "reverse your diabetes" was a phrase responsible doctors were trained not to say. Virta built a company on saying it - and then on publishing the numbers, signing the guarantees, and letting the payers do the math.

The syringe is still in the drawer. Most days, it stays there. That is the whole point.